Clinical Trial Search

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Each H10ssF-6473 Product Administration — 3; 9; 5; 17 Participants

Primary: Proportion of All Participants Negative for Viral RNA on Day 5 — 115; 105 participants — p=0.42

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Each H1ssF_3928 Product Administration — 5; 8; 11; 9 Participants

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Product Administration — 4; 12; 9; 8 Participants

Primary: CD4+ and CD8+ Th1 Cellular Immunogenicity on Day 42 — 0.5; 5.9; 1.0; 0.2 fold change — p=0.45

Primary: Number of Participants With Mild to Moderate Influenza Disease (MMID) — 23; 13; 15; 19 Participants — p=0.03

Primary: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Each HA-F A/Sing Product Administration — 4; 3; 7; 9 Participants

Primary: Safety - Serious Adverse Event — 0; 0; 0 SAEs

Primary: Hemagglutination Inhibition (HI) Antibody Titer — 15.5; 11.4; 139.7; 55.8 titer

Primary: Hemagglutination Inhibition (HI) Antibody Titer — 13.6; 11.6; 165.5; 68.2 titer

Primary: Serum Haemagglutination-inhibition (HI) Antibody Titers Against the Influenza A Virus Strain Subtype H9N2 (Anti-H9N2) — 24.4; 15.6; 14.6; 9.8 Titer

Primary: Number of Participants Reporting Local and Systemic Solicited Reactogenicity Events Post First Vaccination — 24; 25; 23; 23 Participants

Primary: Change in Geometric Mean Titre Ratio, A/H1N1 Strain — 3.13; 3.17 Ratio of Day 0 and Day 21-28 titres

Primary: Haemagglutination Inhibition (HI) Antibody Titers, Against Each of the Vaccine Influenza Virus Strains. — 84.03; 40.48; 306.51; 159.02 Titer

Primary: Area Under the Curve (AUC) of Viral Shedding — 48.56; 25.53 ViralLoad(log(copies/ml))per time(hours) — p=0.31

Primary: Number of Patients With Mild to Moderate Influenza Disease (MMID) — 6; 29 participants

Primary: Number of Patients in Each of 6 Clinical Status Categories on Day 7 — 3; 2; 6; 11 Participants — p=.33

Primary: Hemagglutination Inhibition (HI) Antibody Titers — 19.5; 13.9; 116.0; 47.1 titer

Primary: Number of Laboratory-confirmed Influenza Infections — .22; .14 infections

Primary: Percentage of Participants With Immediate Reactions — 0; 0; 28; 10 Participants

Primary: Area Under the Curve of Virus Load — -2081.98; 18,973.90; 15,944.09; 12,201.14 mins*Eq log10 TCID50/mL

Primary: Percent MMID — 0; 0; 20; 47 percentage of participants

Primary: Occurrence of Adverse Events Related to the Viral Challenge — 0; 0; 1; 6 Occurrence of adverse events

Primary: Degree of Nasopharyngeal Viral Shedding as Determined by Quantitative Polymerase Chain Reaction qPCR — 649.7; 726.1; 646.5; 726.1 hour*Log10 Viral Particles/ ml — p=0.1711

Primary: Number of Participants Having Adverse Events — 0; 1; 1; 1 Participants

Primary: Number of PCR-confirmed Influenza Infections — 17; 3 Participants

Primary: Hemagglutination Inhibition (HAI) Geometric Mean Titer (GMT) Against A/Vietnam/04 Antigen — 14.7; 27.9; 6.7; 13.6 Titer

Primary: Number of Subjects With Solicited Local Symptoms — 212; 16; 39; 3 Participants

Primary: the Serum Antihemagglutinin Antibody Titers and the Derived Parameters Defined in the Committee for Medicinal Products for Human Use (CHMP) Note for Guidance on…

Primary: Frequency Counts and Percentage of Subjects With Adverse Events — 6; 6; 1; 3 Participants